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We studied the possible role of granulocyte neutral proteases as mediators of airway
destruction in patients with cystic fibrosis (CF) who were infected with Pseudomonas
aeruginosa. We measured the enzymatic activities of bronchial secretions on purified
radioactively labeled complement component three (C3), elastin, and a granulocyte elas-
tase-specific substrate. Bronchial secretions from 18 patients with CF who were infected
with P aeruginosa had a significantly higher mean value for C3 cleaving, elastolytic, and
granulocyte elastase-like activity than did two control groups. High enzymatic activities
were observed in patients with CF who have advanced bronchial disease (that had been
determined by a clinical scoring system). Kinetics of proteolysis of radioactively labeled
C3 and inhibition profiles of the activities of the three enzymatic activities studied sug-
gest that they are mainly derived from granulocytes. In addition, 20 of 31 strains of
P aeruginosa isolated from patients with CF inactivated purified ol-antiprotease in
vitro. We postulate that granulocyte neutral proteases and P aeruginosa may act syner-
gistically in the airways of patients with CF and may contribute to the destruction of
elastin and inactivation of C3.
Cystic fibrosis is a fatal hereditary disease, in
which the leading cause of death is respiratory
failure [I]. Patients with cystic fibrosis (CF) usually
have a long history of purulent bronchitis leading
to progressive destruction of small bronchioles and
followed by involvement of the large airways [2].
The pathogens most frequently associated with
these respiratory-tract infections are Staphylococ-
cus aureus and Pseudomonas aeruginosa [2, 3].
Clinical and pathological observations suggest
that progressive airway destruction is accelerated
during infections with P aeruginosa [2]. However,
little information is available regarding the mech-
anisms involved in progressive bronchiolar and
bronchial damage and the persistence of P aerugi-
nosa in bronchial secretions.
Bronchial secretions from patients with CF con-
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tain numerous PMNs [2] that might contribute to
airway damage by release of neutral proteases such
as elastase, collagenase, cathepsin G, and others [4,
5]. These enzymes are indeed able to destroy im-
portant structural proteins of the lung and its air-
ways such as elastin, collagen, and proteoglycans
[4, 5] in vitro; in addition, they can inactivate im-
portant opsonins such as complement component
C3 [6-8] and IgG and IgM immunoglobulins [9-
11]. It is also well established that they are released
extracellularly during phagocytosis [12]. Further-
more, P aeruginosa may secrete an elastase that
destroys the two main inhibitors protecting the
lung and its airways from the activity of PMN
neutral proteases: al-antiprotease [13-16] and the
bronchial mucosal proteinase inhibitor [17]. In
addition, this bacterial elastase is also active on C3
[18] and elastin [15].
We therefore measured the enzymatic activities
of bronchial secretions from patients with CF
(who were infected with P aeruginosa) on purified
human C3, bovine elastin, and a granulocyte elas-
tase-specific substrate. Two groups of patients with
bronchial secretions rich in PMNs (one group with
and the other without bacterial infection of the
tracheobronchial tree) and a granular enzyme
preparation isolated from human PMNs were used
as controls.
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Table 1. Description of patients with cystic fibrosis.
Clinical scores
Patient Age Status Pulmonary Bacteriology
no. (years) and activity findings of sputum
1 18 4 4-5 4
2 18 4-5 4 4
3 14 2 3 4
4 20 3-4 4 4
5 11 2 3 4
6 9 2-3 4 4
7 14 2-3 3 3-4
8 18 2 2-3 3
9 6 1-2 3 3-4
10 20 3-4 4 4
11 14 4 4 4
12 10 2 3 3-4
13 18 2-3 3 4
14 6 2 3 3
15 5 2 2 3
16 5 2 3 4
17 16 4-5 5 5
18 6 4 4 4
NOTE. The scores of the patients were determined accord-
ing to the scoring system of Kraemer et al. [23] by one of the
authors (U.B.S.) unaware of the results of the activities mea-
sured in bronchial secretions.
Patients and Methods
Group 1. Twenty-four samples of bronchial
secretions were collected after chest physiotherapy
from 18 patients with CF, all of whom had P aeru-
ginosa infections (table 1). The patients were either
attending cystic fibrosis clinics or were inpatients
at the children's hospitals, University of Bern or
Geneva, Switzerland. The diagnosis of cystic
fibrosis had been established on clinical features of
the disease and confirmed by sweat sodium and
chloride concentrations above 70 meq/l. The clin-
ical and pulmonary conditions of the patients were
determined by one of the authors who was un-
aware of the laboratory results and were recorded
via a scoring system outlined previously [19].
All but two patients were on similar antibiotic
treatment when the secretions were collected. The
mean age of the patients was 13 years (range, 5-20
years).
Group 2. Twenty samples of bronchial secre-
tions, which fulfilled the quality criteria estab-
lished by Murray and Washington [20], were col-
lected from 20 patients with acute exacerbations of
chronic bronchitis, as documented by chronic
cough, purulent sputum, positive chest findings,
and roentgenograms. In nine patients bronchiec-
tases had been documented by bronchography or
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bronchoscopy. Bronchial lavage fluid was obtained
from six patients by bronchoscopy on the same day
that the sputum samples were obtained. Pathogens
isolated from sputum included: Haemophilus
influenzae [18], Streptococcus pneumoniae [8],
Escherichia coli [1], Proteus vulgaris [1], S aureus
[5], and Aspergillus [1]. Three patients had mixed
infections. Eighteen patients had a history of
smoking. The mean age of the patients was 50
years (range, 9-62 years).
Group 3. Ten samples of bronchial secretions
were obtained as morning specimens from 10 pa-
tients who had no evidence of acute or chronic
respiratory-tract infection. Diagnosis included:
acute asthma (2), pulmonary embolism (1), em-
physema with chronic respiratory failure (1),
chronic heart failure (3), bronchial carcinoma (1),
and metastatic cancer of the lung (1). All patients
produced sputum that was negative when cultured
for pathogens. The mean age of the patients was
68 years (range, 22-90 years).
Processing of bronchial secretions and of
P aeruginosa isolates. Bacterial cultures and
identifications were performed according to well-
established methods. Leukocyte counts in bron-
chial secretions were evaluated semiquantitatively
[20], by a technician unaware of the study results.
The secretions were mixed with a half volume of
sterile isotonic saline and centrifuged within 1 hr
at 1,000 g until the supernatant was clear. The
supernatants were frozen at - 70 C until tested.
Protein concentration was determined by a stan-
dard method (Bio-Rad, Richmond, Calif).
Thirty-one strains of P aeruginosa were isolated
from the bronchial secretions of patients with CF
who were infected with P aeruginosa; the cultures
were maintained in skim milk at - 20 C,.
Microbiological techniques. In order to test the
P aeruginosa strains for elastase productionvquan-
titative cultures were performed as follows: 0.1 ml
of an overnight culture was added to 5 ml of
Mueller-Hinton broth and incubated in a shaking
waterbath at 37 C for 24 hr. The size of the inocu-
lum and the final bacterial concentration were
determined by making plates of serial.dilutions on
Mueller-Hinton agar and counting the colony
forming units. The 24-hr cultures were centrifuged
in an Eppendorf centrifuge at 8,000 g for 10 min
(Eppendorf, Hamburg, FRO). The supernatants
were frozen at - 70 C in small aliquots until used.
Purification of human C3, labeling of C3 with
1251 and preparation of 125I-labeled C3-Sepharose.
C3 was purified to homogeneity from human
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plasma with the use of the method of Tack and
Prahl [22]. It was labeled with 1251 (Amersham
International, Amersham, England), by means of
the chloramine T method [23]. Approximately 1 X
106 counts per minute (cpm) were incorporated
into 1 /Ag of purified C3. Labeled C3 was either
used directly or it was coupled to CnBr-activated
Sepharose 4B (Pharmacia Fine Chemicals,
Uppsala, Sweden) by a standard method.
Assessment of calcium- and magnesium-inde-
pendent C3-cleaving activity. In order to rule out
C3-cleaving activity deriving from complement
convertases, these experiments were performed in
the presence of EDTA (20 mmol final concentra-
tion). 1251-labeled C3-Sepharose beads correspond-
ing to 2 X 105 cpm were suspended in 150 /AI of
calcium- and magnesium-free Dulbecco's PBS (pH
7.4) and incubated with 50 /AI of bronchial secre-
tions that had been previously mixed with EDTA
(20 mmol final concentration), with granular
enzymes, or with P aeruginosa culture super-
natants at 37 C for 5 hr. 1251-labeled C3 fragments
were separated from 1251-labeled C3-Sepharose
beads by centrifugation at 8,000 g for 5 min.
Cleavage of C3 was expressed as the percentage of
cpm in the supernatant divided by the cpm of the
total sample. Spontaneous breakdown of 1251_
labeled C3 incubated alone was 1.2070 ± 0.2%; this
background was subtracted from the results.
Demonstration ofproteolysis of 125I-labeled C3
by polyacrylamide gel electrophoresis [24]. The
kinetics of proteolysis and the pattern of break-
down products of 1251-labeled C3 generated by the
bronchial secretions from a patient with CF and a
P aeruginosa infection were compared with those
obtained from the culture supernatant of a strain
of P aeruginosa from the same patient, and with
those observed when granular enzymes were used.
Four microliters of a bronchial secretion, 34 /AI
of granular enzymes and 240 /AI of the supernatant
from a P aeruginosa culture were incubated with
labeled C3 corresponding to 5 X 106 cpm in 'Iris-
NaCI buffer (pH 7.4) in a total volume of 600 /AI.
Aliquots of 25 /AI were withdrawn after 0, 2, 5, 8,
13, 20, 30, 60, 120, and 300 minutes of incubation
at 37 C and mixed with 12.5 /AI of SDS sample buf-
fer (1% 2-mercaptoethanol, 2% SDS, 80 mmol
Tris-HCI pH 6.8, 10% glycerol, and 0.05% bromo-
phenol-blue) and heated at 100 C for 3 min. The
samples were run on discontinuous slab gels with
5% (wt/vol) acrylamide in the stacking gel and
12.5% (wt/vol) acrylamide in the resolving gel.
Proteins were revealed by autoradiography with a
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Kodak X-omat S film with exposure at - 70 C for
3 hr. Monitoring of molecular weights was accom-
plished with the use of Sendai virus proteins [25],
which were labeled with [35S]methionine as marker
proteins with known molecular weights. Controls
included 1251-labeled C3 incubated both alone and
with saliva from two patients with CF and P aeru-
ginosa infections and from one normal individual.
Preparation of granular enzymes from human
PMNs. Granular enzymes were prepared from
PMNs collected from fresh heparinized blood of
normal adult volunteers, according to the method
of Baggiolini [21] and modified as previously
described [8]. They had an elastolytic activity of
17.4 UE and granulocyte elastase-like activity of
0.59 UTGP (see below for definition of units).
Assessment of elastolytic activity. Elastolytic
activity was measured as described by Hornebeck
[26] with purified bovine elastin (Sigma Co, St.
Louis) radioactively labeled with 3H (New
England Nuclear Corp, Boston). Ten micro-
liters of the test sample were incubated with 500 /Ag
of 3H-Iabeled elastin suspended in 1 ml of Tris (0.1
M, pH 8.2) containing Brij 35 (0.01%) and sodium
azide (0.02%), for 16 hr at 37 C. The samples were
then centrifuged at 3,300 g for 10 min. The radio-
activity of 100fJI of the supernatants was measured
and used to calculate the amount of solubilized
elastin. One milligram of completely solubilized
3H-Iabeled elastin corresponded to 145,000 cpm.
Elastolytic activity (UE) was expressed as the
number of milligrams of labeled elastin solubilized
by 1 ml of enzyme solution.
Measurement of granulocyte elastase-like activ-
ity. Granulocyte elastase-like activity was mea-
sured as previously described [8] with the use of
synthetic Sue-Ala-Ala-Pro-Val-7-amino-4-methyl
coumarin (TGP 928; a gift from M. Baggiolini,
Wander Research Institute, Bern, Switzerland) as a
substrate. The sequence Ala-Ala-Pro-Val has been
shown to be a specific substrate for granulocyte
elastase [27].
The enzymatic activity was expressed in UTGP
= micromoles of 7-amino-5-methyl-coumarin
solubilized per minute by 1 ml of enzyme solution
(extinction coefficient at 360 nm = 12,300). P aer-
uginosa culture supernatants, Mueller-Hinton
broth, saliva from two patients with CF and from
one normal individual had no activity on this
substrate.
Inactivation of partially purified o-l antipro-
tease by supernatants of P aeruginosa cultures. e-I
antiprotease inactivation was measured as follows:
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first, inhibition of 50 IJI of granular enzyme by
increasing concentrations of partially purified 0'-1-
antiprotease (Sigma) was measured; a 100% inhi-
bition was reached by a concentration of 10 IJg of
o-I antiprotease (in 10 IJI). Thereafter, samples of
30 IJI of supernatants of P aeruginosa cultures were
incubated with 60 IJI of Dulbecco's PBS (pH 7.4)
containing 60 IJg of o-I anti protease at 37 C for 24
hr, and the inhibitory activity of 15 IJI of this incu-
bation mixture was tested on 50 IJI of granular
enzyme. o-I antiprotease incubated alone at 37 C
for 24 hr kept its full inhibitory capacity on gran-
ular enzymes; Mueller-Hinton broth had no effect
on either granular enzymes or TGP 928.
Inhibition experiments. Phenylmethylsulfonyl-
fluoride (PMSF, Sigma) [28] was used at 2 mmol
final concentration, Ac-(Ala)4-chloromethylke-
tone at 1 mmol (kindly provided by Dr. J. Powers,
Georgia Institute of Technology, Atlanta) [29],
partially purified o-I antiprotease at 10 IJmol, and
Zincov [30] at 500 IJmol. The results were expressed
as percent inhibition of the enzymatic activity of a
sample. With Ac-(Ala)4-chloromethylketone the
samples were preincubated for 60 min, but with the
other inhibitors the incubation was only for 5 min.
Statistics. The results were expressed as mean
± SEM. For comparison of groups, the Mann-
Whitney U test or Spearman's correlation coeffi-
cient were used. Enzymatic activities within each
group were compared by linear regression analysis
by the method of least squares.
Results
Leukocyte quantitation and protein concentra-
tions of bronchial secretions. Stained smears
showed comparable mean leukocyte scores: group
1,2.3 ± 0.2 (range, 1-3); group 2,2.7 ± 0.2 (range,
2-3); group 3, 2.1 ± 0.1 (range, 2-3). The three
groups of bronchial secretions had a significantly
different mean protein concentration: group 1, 6.3
± 0.9 gil and group 2, 5.1 ± 0.5 gil were signifi-
cantly higher than group 3, 2.7 ± 0.6 gil (P < .01).
Proteolytic and esterolytic activities in bronchial
secretions (figure 1): 125I-labeled C3-c1eaving
activity. In group 1 the mean C3-cleaving activity
was 48.8010 ± 2.5%, a value significantly higher
than that of group 2, which was 15.4% ± 3.5% (P
< .001) and of group 3, which was 7.6010 ± 0.9%
(P < .001). The difference between groups 2 and 3
was also significant (P < .001). The same held true
when the results were expressed per gram of
protein.
Elastolytic activity. The mean elastolytic activ-
125 I-C3
Granulocyte
Elastolytic elastase-like
cleaving activity activity activity
% UE UTGP
60
2 1.5
40
1
1
20 0.5
0 0 0 *
Group II III II III II III
Figure 1. Three enzyme activities were measured in bronchial secretions from three groups of patients: Group 1,
patients with CF infected with P aeruginosa; group 2, patients with exacerbated chronic bronchitis; group 3, patients
with various noninfectious conditions, but with significant numbers of granulocytes in their bronchial secretions.
C3-cleaving activity was determined by measuring the radioactivity of 12sI-Iabeled C3 fragments released into the
supernatant from 12sI-Iabeled C3-Sepharose after incubation with 50 ~l of the bronchial secretion for 5 hr at 37 C.
The results were expressed as the percentage of radioactivity in the supernatant divided by the radioactivity of the
total sample. Elastolytic activity (UE) was expressed as milligrams of 3H-Iabeled elastin hydrolyzed by 1 ml of enzyme
solution after 16 hr of incubation at 37 C. Granulocyte elastase-like activity was measured as UTGP = micromoles
of 7-amino-5-methyl-coumarin released/min per milliliter of enzyme solution.
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Figure 2. The results of enzymatic activities of the 24
hr culture supernatants of 31 strains of P aeruginosa iso-
lated from the patients with CF (group 1) on the substrates
J25I-labeled C3-Sepharose and 3H-labeled elastin were
determined in vitro as described for figure 1. Group A
represents 20 strains of P aeruginosa inactivating o-I
antiprotease as described in material and methods and
group B, 11 strains without effect on o-I antiprotease.
Group A strains were considered as elastase-producing
strains on the basis of their activity on the three substrates
e-I antiprotease, 125I-labeled C3-Sepharose, and 3H-
labeled elastin [18-21].
ity of group 1 was 1.9 ± 0.3 V E compared with
0.54 ± 0.09 (P < .05) in group 2 and 0.04 ± 0.02
(P < .001) in group 3. The difference between
groups 2 and 3 was also significant (P < .01). These
differences were also significant when expressed
per gram of protein.
Granulocyte elastase-like activity. The mean
granulocyte elastase-like activity was strikingly
higher in group 1 than in group 2 bronchial secre-
tions: 1.39 ± 0.56 VTGP vs. 0.12 ± 0.05 UTGP (P
< .001). Group 3 samples had no detectable granu-
locyte elastase-like activity, as was the case in saliva
obtained from two patients with CF and P aerugi-
nosa infections and one normal individual.
In group 1 patients, high clinical scores (which
indicated poor pulmonary condition) correlated
with high 1251-labeled C3-cleaving activitytr, =
.62, P < .01), elastolytic activity (rs = .81, P
< .001), and granulocyte elastase-like activity
(r, = .73, P < .01).
Since the activities of the three enzymes mea-
sured could possibly be attributed to the presence
of PMN neutral proteases [6-8, 29], correlations
between enzymatic activities within each group
were calculated. Group 1: a linear correlation was
found between 125I-labeled C3-cleaving and gran-
ulocyte elastase-like activity (r = .49, P < .025)
and between elastolytic and granulocyte elastase-
like activity (r = .89, P < .001). Group 2: a linear
correlation was observed between 125I-labeled C3-
cleaving and granulocyte elastase-like activity (r
= .48, P < .025), between elastolytic and granulo-
cyte elastase-like activity (r = .56, P < .01),
and between C3-cleaving and elastolytic activity
(r = .49, P < .025).
Heating of both bronchial secretion samples
from three patients with CF and granular enzymes
showed that incubation at 56 C for 30 min inacti-
vated only 10% of the 1251-labeled C3-cleaving
activity of these samples, a finding consistent with
the heat resistance of PMN elastase found by
others [31).
Proteolytic activities of P aeruginosa isolates
from patients with CF (figure 2). The mean bac-
terial concentration of quantitative P aeruginosa
cultures was 3.9 ± 0.4 x 108 cfu/ml. The culture
supernatants were tested for P aeruginosa elastase
by measuring their activity on three substrates
known to be cleaved by P aeruginosa elastase in
vitro: e-I antiprotease [15, 16], 1251-labeled C3 [14],
and 3H-Iabeled elastin [13]. Twenty of the 31
strains of P aeruginosa were shown to inactivate
o-I antiprotease in vitro, as measured by a func-
tional assay: 30 fJI of the culture supernatants of 20
P aeruginosa strains inactivated 60 fJg of e-I anti-
protease completely. The 20 strains inactivating e-I
antiprotease in vitro (figure 2, group A strains)
also had a significantly higher 1251-labeled C3-
cleaving activity (29.6010 ± 3.3010) and elastolytic
activity (1.45 ± 0.31 VE) than did the 11 remain-
ing strains (figure 2, group B strains). C3-cleaving
activity of these strains was 7.6% ± 1% and elasto-
lytic activity 0.24 ± 0.05 VE (P < .(01). In group A
strains there was a linear correlation between 1251_
labeled C3-cleaving and elastolytic activity (r
= .88, P < .001). Finally, there was no correlation
between mucoid appearance and enzyme secretion
of a particular strain; nine group A strains and
four group B strains were mucoid.
Comparison ofproteolytic and esterolytic activ-
ities. With these results at hand, we tried to deter-
mine whether the' levels of enzymatic activity
measured in secretions from patients with CF were
mainly due to enzymes originating from PMNs or
from Pseudomonas strains. To make these deter-
minations, we used time-course and biochemical
patterns of 1251-labeled C3 proteolysis as well as
inhibition experiments for differentiation.
Time course and pattern of proteolysis of 125 1_
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labeled C3. Time course and pattern of proteoly-
sis of 125I-labeled C3 induced by a bronchial secre-
tion from a patient with CF, by the P aeruginosa
culture supernatant of the elastase-producing
strain from the same patient, and by the granular
enzyme preparation were studied in detail as
shown in figure 3. Identical patterns of breakdown
of 125I-labeledC3 by the bronchial secretion and by
the granular enzyme preparation can be recog-
nized: both preparations caused a breakdown of
the alpha chain of 125I-labeled C3 into fragments
with apparent molecular weights of 113 x 103 and
100 x 103 and later, 32 x 103 , 25 x 10\ and 18
x 103 • In contrast, incubation of 125I-labeled C3
with the culture supernatant of the elastase-pro-
ducing strain of P aeruginosa led to a single cleav-
age of the alpha chain with generation of an alpha
fragment of an apparent molecular weight of 110
x 103 and later, two small breakdown products of
16 x 103 and 17 x 103 • Limited fragmentation of
the alpha chain by too Iowan elastase concentra-
tion in the supernatant of the P aeruginosa culture
was excluded by testing the culture supernatant
undiluted, whereas the bronchial secretion and the
granular enzyme preparation were assayed at dilu-
tions of 1:30 and 1:5, respectively. 125I-labeled C3
incubated alone at 37 C for 5 hr showed no evi-
dence of breakdown of either the alpha- or the
beta-chain. Saliva from two patients with CF and
P aeruginosa infections and from one normal indi-
vidual had no effect on 125I-labeled C3.
Figure 3. Four microliters of a cystic fibrosis bronchial
secretion, 34 JAI of granular enzymes, and 240 JAI of the
culture supernatant of the elastase-producing strain of
P aeruginosa from the same patient were incubated at
37 C with 12sI-labeled C3 at a concentration correspond-
ing to 5 x 106 cpm in a total volume of 600 JAI (Tris-NaCI
buffer, pH 7.4). Aliquots of 25 JAI were withdrawn at
various periods of incubation indicated in the figure. The
timed samples were mixed with SDS sample buffer,
heated at 100 C for 3 min, and the resulting breakdown
of 12sI-labeled C3 examined on a 12.5010 polyacrylamide
gel. The arrows ex and (J designate the alpha- and beta-
chain of 12sI-labeled C3; BF corresponds to the buffer
front. The observed proteolysis is restricted to the alpha-
chain and the pattern of breakdown is similar for the
bronchial secretion and for granular enzymes resulting
in alpha-fragments with apparent molecular weights of
100 x 103 and 113 x 103 for the early incubation periods
and small fragments of apparent molecular weights of
3? x 103, 25 X 103 , and 18 x 103 at 5 hr of incubation.
Incubation with the P aeruginosa culture supernatant lead
to only one apparent cleavage of the alpha-chain with a
fragment of apparently 110 x 103 and two small frag-
Discussion
In this study we found that bronchial secretions
from patients with cystic fibrosis (CF) who had
P aeruginosa infections (group 1) had strikingly
higher enzymatic activities on radioactively labeled
C3 and elastin, as well as on a granulocyte elastase-
specific peptide substrate, than did the bronchial
secretions of two control groups, i.e., patients with
chronic bronchitis (group 2) and patients without
infection (group 3; figure 1). Most strains of
P aeruginosa isolated from the patients with CF
secreted bacterial elastase in vitro (figure 2), as
determined by the proteolytic activity of their cul-
ture supernatants on purified e-l antiprotease, C3,
ments of 16 x 103 and 17 x 103 • Molecular weights were
monitored with Sendai virus proteins as marker proteins
[25]; the marker proteins are not shown on the figure.
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and elastin, all three of which are substrates for
this enzyme [13-15, 18]. Each patient was infected
with at least one elastase-producing strain of
P aeruginosa. The following arguments suggest
that the proteolytic activities measured in bron-
chial secretions from patients with CF most likely
derived from granulocyte neutral proteases, i.e.,
elastase and possibly cathepsin G. First, the time-
course of the appearance and the size of break-
down products of 125I-Iabeled C3 were identical
when labeled C3 was incubated with bronchial
secretions from patients with CF and P aeruginosa
infection or with granular enzymes (figure 3), but
it was clearly different when 125I-labeled C3 was
incubated with a P aeruginosa culture superna-
tant. Second, PMSF (an inhibitor of serine-pro-
teases [28J) and Ac-(Ala)4-chloromethylketone (a
granulocyte elastase-specific inhibitor [28]) sub-
stantially suppressed 125I-labeled C3-c1eaving ac-
tivity of both bronchial secretions from a patient
with CF who had P aeruginosa infections and
granular enzymes, but not of supernatants from
P aeruginosa cultures (table 2). The contribution of
complement convertases to 125I-Iabeled C3 break-
down was excluded by measuring 125I-labeled C3-
cleaving activity in the presence of EillA. Among
other proteases possibly involved in C3 cleavage by
bronchial secretions from patients with CF who
had P aeruginosa infections, collagenase is in-
Table 2. Range of inhibition of I 25I-Iabeled C3-cleaving
and granulocyte elastase-like activity by PMSF and Ac-
(Ala)4-chloromethylketone.
-------
Inhibition (070) by inhibitors*
Ac-(Ala)4-
Enzymatic activity PMSF chloromethylketone
C3-cleaving activity of
CF bronchial secretions
(n = 4) 86-95 73-89
Granular enzymes 95 83
P aeruginosa culture
supernatants (2 strains) 0 0
Granulocyte elastase-like
activity of
CF bronchial secretions 100 95-100
Granular enzymes 100 98
NOTE. Granular enzymes and P aeruginosa culture super-
natants were tested in triplicate. Inhibition is expressed as % =
100 (enzymatic activity with the inhibitor )
- enzymatic activity without the inhibitor x 100 .
* The final concentration of the inhibitors was as follows:
PMSF = 2.5 mmol, Ac-(Ala)4-chloromethylketone = 1 mmol.
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hibited by EDTA [28] and is also not inhibited by
the two inhibitors used in the experiment.
Third, three elastases may contribute to mea-
sured elastolytic activity in bronchial secretions of
patients with CF: (1) granulocyte elastase [32], a
serine protease inhibited by PMSF [28], Ac-(Ala)4-
chloromethylketone [27], and its physiological
inhibitor e-I antiprotease [16]; (2) pseudomonas
elastase, a zinc-metalloprotease [14, 18] inhibited
by Zincov [30]; and (3) macrophage elastase [32],
which is a metalloprotease inhibited by a-2 macro-
globulin, but not by e-I antiprotease [31]. Our
inhibition experiments show that the elastolytic
activity of bronchial secretions from patients with
CF was inhibited by the three inhibitors of granu-
locyte elastase, but not by the inhibitor of pseudo-
monas elastase (table 3). Macrophage elastase also
has access to the lung [32], but this enzyme would
not have been inhibited by the inhibitors used [31].
The only other enzyme also known to have some
elastolytic properties [33] and similar inhibition
patterns would be cathepsin G [28].
Fourth, although the substrate we used for
measuring granulocyte elastase-like activity is
specific for granulocyte elastase in purified systems
[27], its specificity cannot be fully demonstrated in
biological fluids. However, the complete inhibition
of granulocyte elastase-like activity by PMSF and
Ac-(Ala)4-chloromethylketone further character-
ized this activity as a serine protease such as elas-
tase. In addition, the linear correlation found be-
tween C3-c1eaving, elastolytic, and granulocyte
elastase-like activity of bronchial secretions from
patients with CF suggest that the three activities
derive from the same group of enzymes. It should
also be noted that when granulocyte elastase is
complexed with a-2 macroglobulin, its second less
important inhibitor in vivo [34], the complex
enzyme-inhibitor still has some activity on small
peptide substrates similar to the one we used [35],
but not on elastin. This may explain why granulo-
cyte elastase-like activity of bronchial secretions
from patients with CF compared with their elasto-
lytic activity was so much higher than granulocyte
elastase-like activity compared with elastolytic
activity of granular enzymes.
Several aspects of our experimental design and
clinical material must be considered. Collecting
bronchial secretions from children is difficult;
thus, we used adults as control patients. Bronchial
secretions from cystic fibrosis patients with
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Table 3. Range of inhibition of elastolytic activity by various inhibitors.
---------------
Inhibition (010) by inhibitor*
Ac-(Ala)4-
Enzyme source PMSF chloromethylketone o-I antiprotease Zincov
CF bronchial secretions (n = 10) 88-97 76-88t 91-99 0
Granular enzymes 87-93 87 89-99 0
P aeruginosa culture super-
natants (2 strains) 4-6 6 0 87-88
-_._._-
-------- ----
NOTE. Granular enzymes and P aeruginosa culture supernatants were tested in triplicate. Inhibition is expressed as
Oli ( enzymatic activity with the inhibitor 00)
o = 100 - _enzymatic activity without the inhibitor x .1 .
* The final concentration of the inhibitors was as follows: PMSF = 2 mmol, Ac-(Ala)4-chloromethylketone 1 mmol,
o-I antiprotease = 10 IAmol, and Zincov = 500 IAmol.
t n = 3.
P aeruginosa infections were obtained by chest
physiotherapy, since, in our centers, it is considered
ethically unjustified to submit patients with CF to
bronchial lavages, which have not demonstrated
therapeutic value. Bronchial lavage fluids could be
obtained from six of our control patients with
chronic bronchitis on the same day as sputum
samples. Proteolytic activities showed good corre-
lation in the six sample pairs. Despite extensive
research, we were unable to find more than three
patients with CF who were not harboring small
quantities of P aeruginosa; these patients were the
ideal control group. All three patients were under
seven years of age, but had proteolytic activities
comparable to adult patients with chronic bron-
chitis.
In our group of patients with CF, high clinical
scores, indicating poor pulmonary condition,
correlated with high proteolytic activities in bron-
chial secretions. This finding may reflect a high
degree of chronic infection leading to accumu-
lation of larger numbers of PMNs or inactivation
of the two most important inhibitors of gran-
ulocyte elastase in the lung by longstanding coloni-
zation or infection with P aeruginosa. Indeed,
P aeruginosa elastase is known to inactivate both
the bronchial mucosal proteinase inhibitor pro-
tecting the airways [36] and a-I antiprotease [16],
and each patient with CF was infected with at least
one elastase-producing strain. Although we cannot
link this in vitro demonstration with inactivation
of inhibitors in vivo, the nearly complete sup-
pression of elastolytic activity of CF bronchial
secretions by purified a-I antiprotease in vitro indi-
cates that in vivo the inhibitor potential for PMN
neutral proteases was too.
Bronchial secretions from patients with CF also
had high proteolytic activity on 125I-Iabeled C3, an
activity most likely originating from PMN neutral
proteases. Since granulocyte elastase in vitro not
only inactivates C3 [6, 7] but also IgG and IgM
[10, 11], it is conceivable that free granulocyte
elastase in vivo leads to functional inactivation of
these opsonins and thereby favors the persistence
of microorganisms, a well known characteristic of
P aeruginosa infections in these patients [2, 3].
From our observations we conclude that the
high proteolytic activities measured in CF bron-
chial secretions most likely reflect the activity of
PMN neutral proteases, especially elastase and
cathepsin G. This free proteolytic activity may be
caused by either an excess of proteolytic enzymes
or a lowered local inhibitor potential, the latter
being induced by P aeruginosa elastase. PMN
neutral proteases may also inactivate opsonins in
the bronchial tree of these patients and therefore
contribute to persistence of microorganisms. In a
prospective study, we currently follow these prote-
olytic activities of bronchial secretions from pa-
tients with CF who had P aeruginosa infections
before and after iv antibiotic therapy against
P aeruginosa and investigate the efficacy of syn-
thetic inhibitors of granulocyte elastase on these
proteolytic activities. Such inhibitors may be
considered as possible adjuncts to antimicrobial
therapy in patients with CF.
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